| abstract |
Provided is a therapeutic agent comprising at least a compound having a β3nagonist activity and one member selected from the group consisting of an anticholinergicnagent, a monoamine reuptake inhibitor, a lipase inhibitor, a selective serotonin reuptakeninhibitor, insulin, an insulin secretagogue, biguanide, an α-glucosidase inhibitor, anninsulin sensitizer, a HMG-CoA reductase inhibitor, an anion exchange resin, a fibric acidnderivative and a nicotinic acid derivative. The β3-agonist has an activity of inhibitingnurinary incontinence. Further, when used together with a remedy for urinarynincontinence such as propiverine, oxybutynin hydrochloride or tolterodine, it exerts annenhanced anti-urinary incontinence effect. When used together with an antiobestic agentnsuch as sibutramine or orlistat, it exerts an enhanced antiobestic effect. When usedntogether with an antidiabetic agent such as insulin, glibenclamide, acarbose ornrosiglitazone, it exerts an enhanced antidiabetic effect. When used together with annantilipemic agent such as bezafibrate or pravastatin, it exerts an enhanced antilipemicneffect. |